SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02684162

SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if giving donor lymphocyte cells and SGI-110 will help control AML and MDS. The safety of this treatment will also be studied.

Status: 
Recruiting
Study Date: 
Wed, 06/01/2016 to Tue, 06/01/2021
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: SGI-110 Starting dose: 40 mg/m2 subcutaneously daily, Days 1 to 5. Procedure: Donor Lymphocyte Infusion On Day 6 of Cycles 2, 4, and 6, participants receive a donor lymphocyte infusion by vein over about 10-30 minutes. Other Names: DLI Stem cell transplantation AlloSCT